BACKGROUND AND OBJECTIVES

High-flow nasal cannula (HFNC) in children hospitalized with bronchiolitis does not significantly improve clinical outcomes but can increase costs and intensive care unit use. Given widespread HFNC use, it is imperative to reduce use. However, there is limited information on key factors that affect deimplementation. To explore acceptability of HFNC deimplementation, perceptions of HFNC benefits, and identify barriers and facilitators to deimplementation.

METHODS

We conducted a study of health care providers that included quantitative survey data supplemented by semistructured interviews. Data were analyzed using univariate tests and thematic content analysis.

RESULTS

A total of 152 (39%) providers completed the survey; 9 participated in interviews. Eighty-three (55%) providers reported feeling positively about deimplementing HFNC. Reports of feeling positively increased as perceived familiarity with evidence increased (P = .04). Physicians were more likely than nurses and respiratory therapists to report feeling positively (P = .003). Hospital setting and years of clinical experience were not associated with feeling positively (P = .98 and .55, respectively). One hundred (66%) providers attributed nonevidence-based clinical benefits to HFNC. Barriers to deimplementation included discomfort with not intervening, perception that HFNC helps, and variation in risk tolerance and clinical experience. Facilitators promoting deimplementation include staff education, a culture of safely doing less, and enhanced multidisciplinary communication.

CONCLUSIONS

Deimplementation of HFNC in children with bronchiolitis is acceptable among providers. Hospital leaders should educate staff, create a culture for safely doing less, and enhance multidisciplinary communication to facilitate deimplementation.

Bronchiolitis is a leading cause of hospitalizations among children younger than aged 2 years.1,2  High-flow nasal cannula (HFNC) is commonly used in treating children hospitalized with bronchiolitis. However, HFNC does not significantly improve clinical outcomes such as length of stay or length of oxygen supplementation and can increase health care costs and pediatric intensive care unit (PICU) use.37  Studies have demonstrated that HFNC can safely be used as a rescue therapy for children who fail standard oxygen therapy without negative impacts on clinical outcomes.810  But despite the lack of significant clinical benefits, HFNC continues to be routinely used as a treatment modality for children with bronchiolitis in all hospital settings.1114 

Deimplementation is the process of reducing or eliminating low-value care. Previous studies have focused on describing the effects of reducing HFNC use on clinical outcomes.1518  Although these studies successfully decreased HFNC use, they leave critical gaps in our understanding of contextual factors affecting deimplementation. Understanding these factors will help support stakeholders interested in reducing HFNC use. Two studies that have examined implementation and deimplementation of diagnostic and treatment modalities in bronchiolitis have established that providers’ experiences and feelings influence the adoption of best practices in children with bronchiolitis19  and identified several factors that should be considered when planning deimplementation efforts.20  However, neither of these studies explored providers’ attitudes specifically regarding HFNC deimplementation. Because HFNC is well-integrated into hospital systems,1114  it is important to understand providers’ perspectives regarding its deimplementation.

Acceptability refers to the degree to which the idea of stopping a practice is perceived as agreeable or satisfactory. If deimplemention of an intervention is considered to have low acceptability, the intervention may not be deimplemented as intended. We predict that deimplementation of HFNC is likely to have low rates of acceptability among health care providers given its widespread use. Understanding acceptability of deimplementing HFNC among health care providers will inform future effective deimplementation strategies.

The purposes of this single-center study were to (1) evaluate acceptability of HFNC deimplementation in children with mild to moderate bronchiolitis, (2) explore perceived benefits of HFNC, and (3) identify barriers and facilitators to HFNC deimplementation.

We conducted a study of health care providers that included quantitative survey data supplemented by a limited number of semistructured interviews. This study was conducted at a large academic children’s hospital in the mid-Atlantic United States with 226 total pediatric beds. Our institution cared for ∼900 children hospitalized with bronchiolitis in 2019. The study included respiratory therapists (RTs), nurses, attending physicians, pediatric resident physicians, and advanced practice providers (APPs). Pediatric resident physicians’ and APPs’ responses were grouped in with the physicians. Participants were recruited via e-mail from the emergency department, general pediatric unit, and PICU. This study took place from July 2021 to September 2021 and was approved by our local institutional review board.

We collected data via electronic surveys and semistructured interviews. Survey questions were developed to collect data on provider characteristics, perceptions of the benefits of HFNC, and acceptability of HFNC deimplementation (Supplemental Fig 2). Survey questions evaluating provider acceptability were informed using the Theoretical Framework for Acceptability (TFA) by Sekohn et al21,22  TFA is a multifaceted framework consisting of constructs that can be applied to assess prospective acceptability of health care interventions from the perspective of those who will deliver it. Acceptability, in regard to deimplementation, refers to the degree to which the idea of stopping a practice is perceived as agreeable, palatable, or satisfactory. A survey question was designed for 6 of the acceptability domains in the TFA (Supplemental Fig 3). These domains were (1) affective attitude, (2) opportunity costs, (3) ethicality, (4) burden, (5) self-efficacy, and (6) intervention coherence.

Survey responses were anonymous unless participants provided their e-mail address indicating their interest to participate in an interview. Surveys were tested by the authors to ensure questions with logic sequencing were working as intended and that questions were written clearly. The survey was then administered electronically through REDCap 10.0.20 (Vanderbilt University, Nashville, TN), a Health Insurance Portability and Accountability Act-compliant software.

Providers indicated willingness to participate in an interview on the electronic survey. Each of these providers were approached via e-mail to participate in a voluntary interview. We conducted a limited number of semistructured interviews to collect in-depth data on facilitators and barriers to HFNC deimplementation. The interview guide was informed by the Consolidated Framework for Implementation Research. The Consolidated Framework for Implementation Research framework consists of 39 constructs that have been associated with effective implementation23 ; we used the 7 constructs most likely to influence HFNC deimplementation to create the interview guide and sought to understand those influences more deeply through in-depth discussion (Supplemental Fig 4). When appropriate, interviewees were asked additional questions to better elucidate individual responses from the electronic survey as well. Interviews were conducted and audio recorded by 2 authors (N.G., and A.N.) using an online conference platform. Audio recordings were manually transcribed by 4 authors.

Acceptability of HFNC Deimplementation

We evaluated 6 outcomes to understand acceptability of HFNC deimplementation. We used affective attitude as a proxy for overall provider acceptability because this outcome refers to how an individual feels about deimplementing an intervention. We used 5 point Likert scales to record all responses. All scales were categorized as negative (numerical value of 1 or 2), neutral (3), or positive (4 or 5) except in regard to familiarity with evidence in which extremely familiar and moderately familiar were positive responses, somewhat familiar and slightly familiar were neutral responses, and not familiar was a negative response. We hypothesized that affective attitudes regarding HFNC deimplementation would differ based on clinical role, primary hospital setting, years of clinical experience, familiarity with HFNC evidence, and presence of a leadership role.

We compared affective attitudes by provider characteristics using Pearson exact χ2, Kruskal-Wallis singly ordered exact, and Wilcoxon-Mann-Whitney exact tests. All analyses were performed with SAS software (v9.4, SAS Institute, Cary, NC) and P values less than .05 were considered statistically significant.

Perceived Benefits of HFNC

Identification of benefits was elicited by responses to the following question on the electronic survey: “Which of the following are benefits to using HFNC? Check all that apply.” Possible benefits included: (1) parent comfort, (2) provider comfort, (3) decrease in length of stay, (4) decrease in length of oxygen supplementation, (5) decrease the risk of intubation, and (6) decrease the risk of PICU transfer. We hypothesized that providers would identify improvements in clinical outcomes (decreased length of stay, length of oxygen supplementation, and risk of PICU transfer) as benefits to using HFNC despite not being evidence-based.

We stratified these responses by clinical role and compared groups using χ2 and Wilcoxon-Mann-Whitney tests. When statistically significant differences were found among the clinical role, a secondary analysis using Pearson χ2 or Fisher exact testing was performed to individually compare physician responses with RT and nurses separately. All quantitative analyses were performed with SAS software (v9.4, SAS Institute, Cary, NC) and P values less than .05 were considered statistically significant.

Barriers and Facilitators to HFNC Deimplementation

Interview data were analyzed using a theory-informed inductive approach to thematic content analysis.24  After the first 7 interviews, 4 authors met to discuss emerging concepts and themes. Following 2 more interviews, the researchers confirmed no new themes were emerging in the data and that they had reached thematic saturation; data collection then ceased. After completing the 9 interviews, the same 4 authors met weekly to develop a codebook and used this to code each transcript. After group-coding while meeting via an online conference platform, the team reviewed the coded data for discrepancies, which were addressed through negotiated consensus. The 3 most common themes for facilitators and barriers were identified and described with exemplary quotes.

We distributed the electronic survey to 387 providers; 152 responded, for an overall 39% response rate. Of the 387 providers approached, 52 (13%) were physicians, 225 (58%) were nurses, 59 (15%) were RTs, 39 (10%) were pediatric residents, and 12 (3%) were APPs. Of the 152 participants who completed the survey, 44 (29%) were physicians/APPs, 78 (51%) were nurses, and 30 (20%) were RTs. Thirty providers (20%) identified their primary setting as the emergency department, 63 (42%) as the general pediatric unit, and 59 (39%) as the PICU. Participants were diverse in terms of clinical role, primary hospital setting, years of clinical experience, familiarity with HFNC evidence, and presence of a leadership role.

Overall, 83 (55%) providers reported feeling positively about deimplementing HFNC, 51 (34%) reported feeling neutrally and 18 (12%) reported feeling negatively. Physicians/APPs (34; 77%) were significantly more likely to report feeling positively about reducing HFNC use compared with nurses (33; 42%) and RTs (16; 53%) (P ≤ .001 and .03, respectively). Providers with leadership roles were more likely to report feeling more positively about reducing HFNC (P = .04). There was no statistically significant difference in reporting feeling positively based on primary hospital setting (P = .98) or years of clinical experience (P = .55). Table 1 describes provider characteristics and compares providers’ affective attitudes in regard to HFNC deimplementation.

TABLE 1

Affective Attitudes Regarding High-Flow Nasal Cannula Deimplementation by Provider Characteristics

Providers Who Felt Positively (n = 73)Providers Who Felt Neutrally (n = 46)Providers Who Felt Negatively (n = 18)P
Clinical role n (%)    .003a 
 Physician 24 (83) 5 (17) 0 (0)  
 Respiratory therapist 16 (53) 11 (37) 3 (10)  
 Nurse 33 (42) 30 (39) 15 (19)  
Primary hospital setting n (%)    .98a 
 Emergency department 15 (52) 11 (38) 3 (10)  
 General pediatric unit 29 (55) 17 (32) 7 (13)  
 Pediatric intensive care unit 29 (53) 18 (32) 8 (15)  
Total years of clinical experience n (%)    .55b 
 0 to <6 y 38 (53) 21 (29%) 13 (18)  
 6‒10 y 21 (62) 7 (21) 6 (18)  
 11‒15 y 14 (56) 10 (40) 1 (4)  
 >15 y 21 (53) 15 (38) 4 (10)  
Familiarity with evidence n (%)    .04a 
 Moderately to extremely 31 (70) 11 (25) 2 (5)  
 Somewhat to slightly 35 (49) 25 (34) 12 (17)  
 Not familiar 7 (33) 10 (48) 4 (19)  
Providers holding leadership roles n (%)    .04c 
 Yes 23 (66) 11 (31) 1 (3)  
 No 50 (49) 35 (33) 17 (17)  
Providers Who Felt Positively (n = 73)Providers Who Felt Neutrally (n = 46)Providers Who Felt Negatively (n = 18)P
Clinical role n (%)    .003a 
 Physician 24 (83) 5 (17) 0 (0)  
 Respiratory therapist 16 (53) 11 (37) 3 (10)  
 Nurse 33 (42) 30 (39) 15 (19)  
Primary hospital setting n (%)    .98a 
 Emergency department 15 (52) 11 (38) 3 (10)  
 General pediatric unit 29 (55) 17 (32) 7 (13)  
 Pediatric intensive care unit 29 (53) 18 (32) 8 (15)  
Total years of clinical experience n (%)    .55b 
 0 to <6 y 38 (53) 21 (29%) 13 (18)  
 6‒10 y 21 (62) 7 (21) 6 (18)  
 11‒15 y 14 (56) 10 (40) 1 (4)  
 >15 y 21 (53) 15 (38) 4 (10)  
Familiarity with evidence n (%)    .04a 
 Moderately to extremely 31 (70) 11 (25) 2 (5)  
 Somewhat to slightly 35 (49) 25 (34) 12 (17)  
 Not familiar 7 (33) 10 (48) 4 (19)  
Providers holding leadership roles n (%)    .04c 
 Yes 23 (66) 11 (31) 1 (3)  
 No 50 (49) 35 (33) 17 (17)  
a

Pearson’s χ2 testing.

b

Kruskal-Wallis singly ordered exact testing.

c

Wilcoxon-Mann-Whitney testing.

Providers who reported being at least moderately familiar with HFNC evidence (33; 72%) were more likely to report feeling positively about deimplementing HFNC compared with those who reported being less familiar with HFNC evidence (P = .04). Figure 1 illustrates the acceptability of HFNC deimplementation based on each individual outcome.

FIGURE 1

Acceptability of high-flow nasal cannula deimplementation. Responses fit the very negative to very positive, with the middle being neutral, except for questions about effort: great deal and much effort (negative), some effort (neutral), little and no effort (positive); and familiarity with evidence: extremely and moderately familiar (positive), somewhat and slightly familiar (neutral), and not familiar (negative).

FIGURE 1

Acceptability of high-flow nasal cannula deimplementation. Responses fit the very negative to very positive, with the middle being neutral, except for questions about effort: great deal and much effort (negative), some effort (neutral), little and no effort (positive); and familiarity with evidence: extremely and moderately familiar (positive), somewhat and slightly familiar (neutral), and not familiar (negative).

Close modal

Providers attributed nonevidence-based clinical benefits to HFNC: 51 (34%) reported decreased length of stay, 57 (38%) reported decreased length of oxygen supplementation, and 79 (52%) reported decreased risk of PICU transfer. Overall, we found that 100 (66%) participants believe HFNC improves at least 1 of these clinical outcomes despite being nonevidence-based. RTs (27; 90%) were significantly more likely to report a nonevidence-based clinical benefit of HFNC than physicians/APPs (14; 32%) (P ≤ .001). Among all providers, 97 (64%) reported decreased risk of intubation as a benefit of HFNC, a benefit that aligns with current evidence.

Of all the participants, 58 (38%) reported provider comfort and 70 (46%) reported parent comfort as a benefit of HFNC. Conversely, physicians/APPs were significantly more likely to report provider and parent comfort as a benefit of HFNC compared with RTs (P = .004 for both comparisons) but not nurses (P = .05 and P = .08, respectively). Table 2 illustrates perceived benefits of HFNC by clinical role.

TABLE 2

Perceived Benefits of High-Flow Nasal Cannula by Clinical Role

Physician (n = 29)Respiratory Therapist (n = 30)Nurse (n = 78)P
Comfort to families n (%) 19 (66) 8 (27) 35 (45) .01a 
Comfort to providers n (%) 16 (55) 6 (20) 28 (36) .02a 
Decreases the risk of intubation n (%) 11 (38) 26 (87) 54 (69) .07b 
Decreases the risk of PICU transfer n (%) 8 (28) 24 (80) 44 (56) <.001a 
Decreases length of oxygen supplementation n (%) 0 (0) 15 (50) 41 (53) <.001b 
Decreases length of stay n (%) 0 (0) 16 (53) 33 (42) .003b 
Holds at least 1 perception of clinical benefit that is not evidence-based n (%)c 8 (28) 27 (90) 59 (76) <.001b 
None of the above n (%) 3 (10) 1 (3) 7 (9) .91b 
Physician (n = 29)Respiratory Therapist (n = 30)Nurse (n = 78)P
Comfort to families n (%) 19 (66) 8 (27) 35 (45) .01a 
Comfort to providers n (%) 16 (55) 6 (20) 28 (36) .02a 
Decreases the risk of intubation n (%) 11 (38) 26 (87) 54 (69) .07b 
Decreases the risk of PICU transfer n (%) 8 (28) 24 (80) 44 (56) <.001a 
Decreases length of oxygen supplementation n (%) 0 (0) 15 (50) 41 (53) <.001b 
Decreases length of stay n (%) 0 (0) 16 (53) 33 (42) .003b 
Holds at least 1 perception of clinical benefit that is not evidence-based n (%)c 8 (28) 27 (90) 59 (76) <.001b 
None of the above n (%) 3 (10) 1 (3) 7 (9) .91b 

Abbreviation: PICU, pediatric intensive care unit.

a

χ2 testing.

b

Wilcoxon-Mann-Whitney testing.

c

Clinical benefits that are not evidence-based: decreased risk of PICU transfer, length of oxygen therapy, or length of stay.

A total of 35 providers indicated willingness to participate in an interview in the electronic survey; 19 were physicians/APPs, 12 were nurses, and 4 were RTs. We conducted 9 semistructured interviews: 1 RT, 4 nurses, and 4 physicians.

We identified several barriers and facilitators to HFNC deimplementation. The 3 most common barriers included the following: (1) discomfort with not intervening, (2) perception that HFNC helps, and (3) variation in risk tolerance and clinical experience. The 3 most common facilitators included (1) staff education, (2) a culture of safely doing less, and (3) enhanced interdisciplinary communication. Each facilitator naturally addressed each barrier. These are described in Table 3 with exemplary quotes and suggested interventions that were drawn from the interviews.

TABLE 3

Barriers and Facilitators to HFNC Deimplementation With Exemplary Quotes and Suggested Interventions

BarrierFacilitatorSuggested Interventions
Perception that HFNC helps
“[When you put a patient on HFNC], they often become more comfortable, so sometimes it really helps…and if you have seen it work, then you are more likely to want to expand the use of that tool.” (Pediatric ICU attending)
“We told ourselves that it makes the patient look better because … that's the only thing we have to offer, even though there's probably a cost to that. Arguably, we aren't really changing outcomes but then we will say ‘well they look more comfortable.’” (Pediatric ED attending) 
Access to education
“[Having] some education about evidence-based practice on how it doesn’t really help their length of stay… showing this actually isn’t helping that much then maybe that would change my mind.” (Pediatric ward nurse)
“I think a true roll out of education, not just sending out a protocol… but having someone come in and talk to all providers, address our assessment skills, [and] focus on sharing research.” (Pediatric ward respiratory therapist) 
• Review of bronchiolitis and HFNC physiology
• Provide a summary of the evidence of HFNC’s impact on clinical outcomes
• Reminders before bronchiolitis season on the evidence 
Discomfort with not intervening
“I think oftentimes the initiation comes from a drive to want to feel like we are doing something. One of the hardest things in medicine I think is sitting back and not intervening and just giving patients time to heal.” (Pediatric hospitalist attending)
“All the data out there is saying none of this stuff works. But we can’t help it, we have to do something. The idea of admitting a patient into the hospital and just sitting there and not doing anything seems to drive people mad.” (Pediatric ED attending) 
Adopting a culture of safely doing less
“Part of it I think is culture change. The whole concept of safely doing less… trying to incorporate into our culture it’s okay to not intervene sometimes.” (Pediatric hospitalist attending)
“Creating a pathway… and giving permission to do nothing in a formal accredited way. It’s okay to sit and watch these kids and I think that’s really hard for people, but if it’s encouraged by the institution, then there’s a lot of freedom there.” (Pediatric ED attending) 
• Create a HFNC pathway
• Identify department champions
• Audit and feedback on the impact of deimplementation on clinical outcomes locally
• Alternative interventions
• Committee to share new initiatives/policies
• Obtain leadership buy-in 
Variation in provider risk tolerance and experience
“Everyone [has] a different view on how sick a patient is, what their tolerance is, and how they define sick.” (Pediatric ED attending)
“Sometimes [the] respiratory [therapist] will have a different opinion than the [physician].” (Pediatric ward nurse) 
Enhanced multidisciplinary communication
“Checking in more frequently will make people feel more comfortable even though we’re not doing anything…[and hearing] ‘we’ll keep an eye on them.’” (Pediatric ward nurse)
“[Having physicians and nurses] go look at the patient together… show me what [they’re] seeing and what [their] ideas are and how that’s going to help us.” (Pediatric ward nurse) 
• Perform a team huddle
• Review of clinical findings in a patient with respiratory distress
• Multidisciplinary education 
BarrierFacilitatorSuggested Interventions
Perception that HFNC helps
“[When you put a patient on HFNC], they often become more comfortable, so sometimes it really helps…and if you have seen it work, then you are more likely to want to expand the use of that tool.” (Pediatric ICU attending)
“We told ourselves that it makes the patient look better because … that's the only thing we have to offer, even though there's probably a cost to that. Arguably, we aren't really changing outcomes but then we will say ‘well they look more comfortable.’” (Pediatric ED attending) 
Access to education
“[Having] some education about evidence-based practice on how it doesn’t really help their length of stay… showing this actually isn’t helping that much then maybe that would change my mind.” (Pediatric ward nurse)
“I think a true roll out of education, not just sending out a protocol… but having someone come in and talk to all providers, address our assessment skills, [and] focus on sharing research.” (Pediatric ward respiratory therapist) 
• Review of bronchiolitis and HFNC physiology
• Provide a summary of the evidence of HFNC’s impact on clinical outcomes
• Reminders before bronchiolitis season on the evidence 
Discomfort with not intervening
“I think oftentimes the initiation comes from a drive to want to feel like we are doing something. One of the hardest things in medicine I think is sitting back and not intervening and just giving patients time to heal.” (Pediatric hospitalist attending)
“All the data out there is saying none of this stuff works. But we can’t help it, we have to do something. The idea of admitting a patient into the hospital and just sitting there and not doing anything seems to drive people mad.” (Pediatric ED attending) 
Adopting a culture of safely doing less
“Part of it I think is culture change. The whole concept of safely doing less… trying to incorporate into our culture it’s okay to not intervene sometimes.” (Pediatric hospitalist attending)
“Creating a pathway… and giving permission to do nothing in a formal accredited way. It’s okay to sit and watch these kids and I think that’s really hard for people, but if it’s encouraged by the institution, then there’s a lot of freedom there.” (Pediatric ED attending) 
• Create a HFNC pathway
• Identify department champions
• Audit and feedback on the impact of deimplementation on clinical outcomes locally
• Alternative interventions
• Committee to share new initiatives/policies
• Obtain leadership buy-in 
Variation in provider risk tolerance and experience
“Everyone [has] a different view on how sick a patient is, what their tolerance is, and how they define sick.” (Pediatric ED attending)
“Sometimes [the] respiratory [therapist] will have a different opinion than the [physician].” (Pediatric ward nurse) 
Enhanced multidisciplinary communication
“Checking in more frequently will make people feel more comfortable even though we’re not doing anything…[and hearing] ‘we’ll keep an eye on them.’” (Pediatric ward nurse)
“[Having physicians and nurses] go look at the patient together… show me what [they’re] seeing and what [their] ideas are and how that’s going to help us.” (Pediatric ward nurse) 
• Perform a team huddle
• Review of clinical findings in a patient with respiratory distress
• Multidisciplinary education 

Abbreviations: ED, emergency department; HFNC, high-flow nasal cannula; ICU, intensive care unit.

Reducing the use of HFNC in children with bronchiolitis is an important area of pediatric research. However, to the best of our knowledge, no previous studies have assessed the acceptability of deimplementing HFNC among providers. Overall, providers found deimplementation acceptable with most reporting feeling positively about reducing HFNC use in children with mild to moderate bronchiolitis and very few feeling negatively. We also found that most participants believe HFNC improves at least 1 clinical outcome that is not evidence-based. Finally, we identified several barriers to deimplementation: discomfort with not intervening, perception that HFNC helps, and variation in risk tolerance and clinical experience. Providers also described facilitators such as staff education, a culture of safely doing less, and enhanced multidisciplinary communication. Hospital leaders interested in improving the care of children hospitalized with bronchiolitis can leverage these findings to inform future HFNC deimplementation efforts.

To successfully deimplement nonevidence-based interventions, we must understand providers’ attitudes toward acceptability.25,26  This is supported by Tyler et al,’s findings that provider attitudes influence adoption of best practices, and that providers at high-using hospitals worry about the potential harms of doing less, whereas those at low-using hospitals focus on the potential harms of unnecessary treatments.19  This phenomenon was similarly described by Charvat et al., who encountered uncertainty and discomfort among RTs and nurses regarding weaning HFNC as the authors strove to reduce HFNC duration.17  Our study elicited similar attitudes; however, overall we noted that most providers found it acceptable to deimplement HFNC. Our study adds to the literature by describing the differences in the acceptability by provider characteristics: acceptability varied by clinical role, but not by years of clinical experience or primary hospital setting. Our study also adds that providers who were more familiar with the evidence were more likely to find HFNC deimplementation acceptable. Thus, access to literature illustrating the lack of significant improvements in clinical outcomes with HFNC may increase acceptability and support HFNC deimplementation.

Although a level of acceptability is necessary, it is not sufficient. There are well-established factors that can affect the adoption of interventions that have been applied toward deimplementation. However, there are distinct factors associated with the discontinuation of established practices that are not as well understood. Staff education on the evidence, communication, and permission to change are facilitators congruent with those described by McDaniel et al.’s work exploring physician experience with deimplementation.20  Additional facilitators described by this study include stakeholder engagement, normalization, and preempting expectations of action. In addition, both studies describe provider fear or discomfort with doing less as barriers to deimplementation. Our study additionally described the variation in risk tolerance and clinical experience as a barrier to deimplementation. Although McDaniel et al,’s study was limited to physicians, our study identified similar findings among nurses and RTs.

Providers identified the importance of developing a culture of safely doing less as a key facilitator of HFNC deimplementation. A study by Haskell et al described theory-based strategies to reduce the use of low-value interventions, such as antibiotics and steroids, in children with bronchiolitis.27  Although this study did not specifically address HFNC, the interventions described are similar to those elicited in our interviews. Participants suggested the following as interventions: use of departmental champions to motivate individuals, creation of clinical pathways that prompt recommended behaviors and allow providers to do less in a formal way, dissemination of education, cultivation of multidisciplinary relationships, and real-time results on the impact of deimplementation efforts to alleviate provider fear of potential negative consequences. These strategies can be leveraged by hospital leaders to create a culture for safely doing less. Given the striking impact of local culture on deimplementation efforts19,20  and the differences in acceptability of deimplementation across provider roles, investigating specific barriers and facilitators across roles and the impact of mitigation strategies by role is an important area for future research.

Limitations of this research should be considered for the generalizability of our findings. First, the study was conducted at a single academic site that may have meaningful differences from other institutions. Second, only 39% of providers completed the survey and a limited number completed interviews. We noted that those finding HFNC deimplementation more acceptable were more willing to participate in the survey and interviews, suggesting a nonresponse or participation bias. Of those who were interviewed, all reported feeling neutral or positive regarding HFNC deimplementation on the electronic survey. Although we identified 3 providers willing to participate in an interview who reported feeling negatively, these providers were ultimately not available to be interviewed. Furthermore, although acceptability among providers in their first few years of practicing clinically may differ from those with more years of experience, we were unable to analyze acceptability among providers with fewer than 6 years of experience. Last, although we reached thematic saturation among those who felt neutrally or positively, obtaining a better understanding of those who felt negatively may inform different barriers and facilitators, and thus, is an important area for future research.

Our study provides insight into the acceptability of HFNC deimplementation in children hospitalized with bronchiolitis. Providers commonly attributed improvements in clinical outcomes as a benefit for using HFNC despite not being evidence-based. Nevertheless, we found that HFNC deimplementation is acceptable among most providers in different roles and hospital settings. Hospital leaders should incorporate staff education, a culture for safely doing less, and enhanced multidisciplinary communication to facilitate HFNC deimplementation.

The authors acknowledge Mike Sheridan and all staff members at our institution who made this study possible. Deidentified individual participant data will not be made available.

FUNDING: No external funding.

CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no potential conflicts of interest to disclose.

Drs Gupta, Port, and Jo, and Ms Newcomb conceptualized and designed the study, designed the data collection instruments, conducted data collection, carried out the analyses, and drafted the initial manuscript. Drs Bastawrous, Busch, and Weis conceptualized and designed the study, conducted data collection, interpreted the data, critically reviewed and revised the manuscript, and approved the final manuscript as submitted.

1.
Hasegawa
K
,
Tsugawa
Y
,
Brown
DF
,
Mansbach
JM
,
Camargo
CA
Jr
.
Trends in bronchiolitis hospitalizations in the United States, 2000-2009
.
Pediatrics
.
2013
;
132
(
1
):
28
36
2.
Fujiogi
M
,
Goto
T
,
Yasunaga
H
, et al
.
Trends in bronchiolitis hospitalizations in the United States: 2000-2016
.
Pediatrics
.
2019
;
144
(
6
):
e20192614
3.
Lin
J
,
Zhang
Y
,
Xiong
L
,
Liu
S
,
Gong
C
,
Dai
J
.
High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis
.
Arch Dis Child
.
2019
;
104
(
6
):
564
576
4.
Gc
VS
,
Franklin
D
,
Whitty
JA
, et al
.
First-line oxygen therapy with high-flow in bronchiolitis is not cost saving for the health service
.
Arch Dis Child
.
2020
;
105
(
10
):
975
980
5.
Coon
ER
,
Stoddard
G
,
Brady
PW
.
Intensive care unit utilization after adoption of a ward-based high-flow nasal cannula protocol
.
J Hosp Med
.
2020
;
15
(
6
):
325
330
6.
Willer
RJ
,
Coon
ER
,
Harrison
WN
,
Ralston
SL
.
Trends in hospital costs and levels of services provided for children with bronchiolitis treated in children’s hospitals
.
JAMA Netw Open
.
2021
;
4
(
10
):
e2129920
7.
Biggerstaff
S
,
Markham
JL
,
Winer
JC
,
Richardson
T
,
Berg
KJ
.
Impact of high flow nasal cannula on resource utilization in bronchiolitis. [published online ahead of print, December 23, 2021]
.
Hosp Pediatr
.
8.
Kepreotes
E
,
Whitehead
B
,
Attia
J
, et al
.
High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial
.
Lancet
.
2017
;
389
(
10072
):
930
939
9.
Franklin
D
,
Babl
FE
,
Schlapbach
LJ
, et al
.
A randomized trial of high-flow oxygen therapy in infants with bronchiolitis
.
N Engl J Med
.
2018
;
378
(
12
):
1121
1131
10.
O’Brien
S
,
Craig
S
,
Babl
FE
,
Borland
ML
,
Oakley
E
,
Dalziel
SR
;
Paediatric Research in Emergency Departments International Collaborative (PREDICT) Network, Australasia
.
Rational use of high-flow therapy in infants with bronchiolitis. What do the latest trials tell us? A Paediatric Research in Emergency Departments International Collaborative perspective
.
J Paediatr Child Health
.
2019
;
55
(
7
):
746
752
11.
Zemach
S
,
Helviz
Y
,
Shitrit
M
,
Friedman
R
,
Levin
PD
.
The Use of high-flow nasal cannula oxygen outside the ICU
.
Respir Care
.
2019
;
64
(
11
):
1333
1342
12.
Kalburgi
S
,
Halley
T
.
High-flow nasal cannula use outside of the ICU setting
.
Pediatrics
.
2020
;
146
(
5
):
e20194083
13.
Lipshaw
MJ
,
Vukovic
AA
,
Dean
P
, et al
.
High-flow nasal cannula in bronchiolitis at a pediatric emergency department: trends and outcomes
.
Hosp Pediatr
.
2021
;
11
(
2
):
119
125
14.
Riese
J
,
Porter
T
,
Fierce
J
,
Riese
A
,
Richardson
T
,
Alverson
BK
.
Clinical outcomes of bronchiolitis after implementation of a general ward high flow nasal cannula guideline
.
Hosp Pediatr
.
2017
;
7
(
4
):
197
203
15.
Betters
KA
,
Hebbar
KB
,
McCracken
C
,
Heitz
D
,
Sparacino
S
,
Petrillo
T
.
A Novel weaning protocol for high-flow nasal cannula in the PICU
.
Pediatr Crit Care Med
.
2017
;
18
(
7
):
e274
e280
16.
Siraj
S
,
Compton
B
,
Russell
B
,
Ralston
S
.
Reducing high-flow nasal cannula overutilization in viral bronchiolitis
.
Pediatr Qual Saf
.
2021
;
6
(
4
):
e420
17.
Charvat
C
,
Jain
S
,
Orenstein
EW
,
Miller
L
,
Edmond
M
,
Sanders
R
.
Quality initiative to reduce high-flow nasal cannula duration and length of stay in bronchiolitis
.
Hosp Pediatr
.
2021
;
11
(
4
):
309
318
18.
Noelck
M
,
Foster
A
,
Kelly
S
, et al
.
SCRATCH trial: an initiative to reduce excess use of high-flow nasal cannula
.
Hosp Pediatr
.
2021
;
11
(
4
):
319
326
19.
Tyler
A
,
Dempsey
A
,
Spencer
S
, et al
.
Do the guidelines apply? A multisite, combined stakeholder qualitative case study to understand care decisions in bronchiolitis
.
Acad Pediatr
.
2021
;
22
(
5
):
806
817
20.
McDaniel
CE
,
House
SA
,
Ralston
SL
.
Behavioral and psychological aspects of the physician experience with deimplementation
.
Pediatr Qual Saf
.
2022
;
7
(
1
):
e524
21.
Sekhon
M
,
Cartwright
M
,
Francis
JJ
.
Acceptability of health care interventions: a theoretical framework and proposed research agenda
.
Br J Health Psychol
.
2018
;
23
(
3
):
519
531
22.
Sekhon
M
,
Cartwright
M
,
Francis
JJ
.
Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions
.
BMC Health Serv Res
.
2022
;
22
(
1
):
279
.
Published 2022 Mar 1
23.
Damschroder
LJ
,
Aron
DC
,
Keith
RE
,
Kirsh
SR
,
Alexander
JA
,
Lowery
JC
.
Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
.
Implement Sci
.
2009
;
4
:
50
24.
Guest
G
,
MacQueen
KM
,
Namey
EE
.
Applied thematic analysis
.
Newburg Park, CA
:
SAGE Publications, Inc.
;
2012
25.
McKay
VR
,
Morshed
AB
,
Brownson
RC
,
Proctor
EK
,
Prusaczyk
B
.
Letting go: conceptualizing intervention de-implementation in public health and social service settings
.
Am J Community Psychol
.
2018
;
62
(
1-2
):
189
202
26.
Prusaczyk
B
,
Swindle
T
,
Curran
G
.
Defining and conceptualizing outcomes for de-implementation: key distinctions from implementation outcomes
.
Implement Sci Commun
.
2020
;
1
:
43
27.
Haskell
L
,
Tavender
EJ
,
Wilson
CL
, et al
.
Development of targeted, theory-informed interventions to improve bronchiolitis management
.
BMC Health Serv Res
.
2021
;
21
(
1
):
769

Supplementary data